Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer

  title={Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer},
  author={Yixin Wang and Jan G. M. Klijn and Yi Zhang and Anieta M. Sieuwerts and Maxime P. Look and Fei Yang and Dmitri Talantov and Mieke Timmermans and Marion E. Meijer-van Gelder and Jack Yu and Tim Jatkoe and Els M.J.J. Berns and David Atkins and John A. Foekens},
  journal={The Lancet},

Figures and Tables from this paper

Gene expression variation to predict 10-year survival in lymph-node-negative breast cancer

A list of 51 genes derived in this study might have potential for clinical utility as a prognostic gene set, and may include candidate genes of potential relevance for clinical outcome in breast cancer.

Long non-coding RNA expression profiles predict metastasis in lymph node-negative breast cancer independently of traditional prognostic markers

It is suggested that lncRNA profiles provide additional prognostic information and may contribute to the identification of early breast cancer patients eligible for adjuvant therapy, as well as early breast cancers patients that could avoid unnecessary systemic adjUvant therapy.

Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature

The 14-gene signature found to be significantly associated with risk of distant metastasis has a predominance of proliferation genes which have prognostic significance above that of Ki-67 LI and may aid in prioritizing future mechanistic studies and therapeutic interventions.

Differentially expressed genes between primary cancer and paired lymph node metastases predict clinical outcome of node-positive breast cancer patients

The gene signature consisting of 79 differentially expressed genes between primary cancers and lymph node metastases could also predict clinical outcome of node-positive patients, and that the molecular classification based on the gene signature could guide patient-tailored therapy.

Gene Expression Profile Assays as Predictors of Distant Recurrence-Free Survival in Early-Stage Breast Cancer

The analysis reported here is part of an ongoing effort to systematically review the test performance of various classes of gene expression signatures in women with ESBC and to explore any source of heterogeneity observed.

A 39-gene signature is associated with early occurrence of distant metastasis in primary lymph-node negative breast cancers.

A 39-gene signature is developed that can robustly predict early distant metastasis for patients with primary node-negative breast cancer, which exhibited a significant association with ER negative status and more aggressive molecular subtypes in all three datasets, and with poor differentiation status in two datasets.

Detection of gene expression in sentinel lymph node of primary breast cancer patients.

The negative reported lymph nodes for metastasis, had micro metastasis in significant values, and it is suggested that finding clear role for these genes with tumor's outcome, needs to be established.

A Gene Expression Signature that Can Predict the Recurrence of Tamoxifen-Treated Primary Breast Cancer

A molecular signature specifying a subgroup of patients who do not gain benefits from tamoxifen treatment is identified and these patients may therefore be eligible for alternative endocrine therapies and/or chemotherapy.

High Expression of Three-Gene Signature Improves Prediction of Relapse-Free Survival in Estrogen Receptor-Positive and Node-Positive Breast Tumors

The validated three-gene signature sets for ERα (+) cohort, and ERα and node (+) cohorts may have potential clinical utility since they demonstrated predictive and prognostic ability in three independent public data sets.

Copy number alterations that predict metastatic capability of human breast cancer.

The study shows the feasibility of using copy number alterations to predict patient prognostic outcome and when combined with gene expression-based signatures for prognosis, the CNS refines risk classification and can help identify those breast cancer patients who have a significantly worse outlook in prognosis and a potential differential response to chemotherapeutic drugs.



Gene expression profiling predicts clinical outcome of breast cancer

DNA microarray analysis on primary breast tumours of 117 young patients is used and supervised classification is applied to identify a gene expression signature strongly predictive of a short interval to distant metastases (‘poor prognosis’ signature) in patients without tumour cells in local lymph nodes at diagnosis, providing a strategy to select patients who would benefit from adjuvant therapy.

Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer.

The clinical value of these markers is that the patients at a high predicted risk of relapse (13-fold risk) could be upstaged to receive adjuvant therapy, similar to Dukes' C patients.

Breast cancer classification and prognosis based on gene expression profiles from a population-based study

  • C. SotiriouS. Neo E. Liu
  • Biology
    Proceedings of the National Academy of Sciences of the United States of America
  • 2003
Gene expression patterns were found to be strongly associated with estrogen receptor (ER) status and moderately associated with grade, but not associated with menopausal status, nodal status, or tumor size, in an unselected group of 99 node-negative and node-positive breast cancer patients.

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Survival analyses on a subcohort of patients with locally advanced breast cancer uniformly treated in a prospective study showed significantly different outcomes for the patients belonging to the various groups, including a poor prognosis for the basal-like subtype and a significant difference in outcome for the two estrogen receptor-positive groups.

Repeated observation of breast tumor subtypes in independent gene expression data sets

The results strongly support the idea that many of these breast tumor subtypes represent biologically distinct disease entities.

Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns.

The results provide evidence that ER+ and ER- tumors display remarkably different gene-expression phenotypes not solely explained by differences in estrogen responsiveness, and could accurately predict ER status even when excluding top discriminator genes, including ER itself.

Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer

This study supports the suitability of FNA-derived cDNA microarray expression profiling of breast cancers as a comprehensive genomic approach for studying the mechanisms of drug resistance and suggests that these approaches might yield useful results when validated by larger studies.